Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Featured News

    Countermeasure Development: First Ever FDA Qualification of Clinical Safety Biomarker

    By Global Biodefense StaffOctober 29, 2018
    Drug Development for Biodefense
    Share
    Facebook LinkedIn Reddit Email

    The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety biomarker awarded by the U.S. Food and Drug Administration (FDA).

    This significant achievement will improve the detection of drug-induced kidney injury in early phase drug development, helping to improve the development of safe and effective medical countermeasures and disease therapeutics where concern has been raised that an investigational drug may cause kidney injury.

    This qualification applies to a single composite measure of six urine biomarkers, to be used in conjunction with traditional measures of kidney function. It measures the change over time of the urine biomarkers that the team selected for tracking acute damage to the kidney tubules.

    The qualification submission to the FDA included analyses of data collected from a Normal Healthy Volunteer Study funded by the PSTC and a collaborative Harvard-Merck Study of cancer patients with mesothelioma treated with cisplatin, a common chemotherapy drug known to cause kidney injury.

    In achieving this milestone, PSTC, C-Path’s longest running consortium, celebrates the successful translation of its preclinical biomarkers previously qualified for use in animal studies, for use now in Phase 1 clinical trials. “The acceptance of these clinical safety biomarkers marks our first successful translation of biomarkers qualified for preclinical use to use in clinical drug development. This is a major step forward in our efforts to accelerate the development of safer medicines for patients in need,” said Dr. John-Michael Sauer, Executive Director, PSTC.

    Funding for this project was provided by Amgen, Inc., AstraZeneca, C-Path, Johnson & Johnson, Eli Lilly and Company, Merck and Pfizer. This achievement was made possible by the collective efforts of the Clinical Evaluation and Qualification of Translational Kidney Safety Biomarkers Project (Kidney Safety Project) team. Its members include the FNIH, C-Path’s PSTC Nephrotoxicity Working Group, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), academia and industry, with advice from the FDA.

    Source: C-Path

    Biomarkers Clinical Trials
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleAbductions and Attacks in Ebola Outbreak Area, African Swine Fever, mRNA Vaccines
    Next Article New Biomarkers Associated with Protection by RTS,S Malaria Vaccine

    Related Stories

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.